5:48 PM
 | 
Oct 22, 2013
 |  BC Extra  |  Company News

Cubist submits tedizolid NDA, reports 3Q13 earnings

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) reported 3Q13 revenues that missed the Street on Tuesday and separately announced that it submitted an NDA to FDA for tedizolid to treat acute bacterial skin and skin structure infections (ABSSSI).

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >